Updated Jul 16, 2026
Klee Justin B. is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $3.10M.

Justin B. Klee is the Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases. He has been involved in the company's operations and strategic direction, contributing to its mission of addressing serious health challenges.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-09 | AMLX | Amylyx Pharmaceuticals, Inc. | A — Grant or award | 248.9K | $0.00 | |
| 2026-03-04 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 29.3K | $14.47 | $424K |
| 2026-02-04 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 15.5K | $14.69 | $228K |
| 2026-01-21 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 2.0K | $13.89 | $28K |
| 2026-01-21 | AMLX | Amylyx Pharmaceuticals, Inc. | M — Option exercise | 2.8K | $7.57 | $22K |
| 2026-01-21 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 136.2K | $13.58 | $1.85M |
| 2026-01-21 | AMLX | Amylyx Pharmaceuticals, Inc. | M — Option exercise | 197.2K | $7.57 | $1.49M |
| 2026-01-08 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 7.7K | $11.09 | $86K |
| 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 200 | $15.01 | $3K |
| 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 29.8K | $14.37 | $428K |
| 2024-11-06 | AMLX | Amylyx Pharmaceuticals, Inc. | M — Option exercise | 63.7K | $1.57 | $100K |
| 2024-10-02 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 18.6K | $3.20 | $59K |
Justin B. Klee is the Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases. He has been involved in the company's operations and strategic direction, contributing to its mission of addressing serious health challenges.…
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($3.10M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Klee Justin B. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.